New hope for advanced cancer patients after standard treatments fail
NCT ID NCT07215637
Summary
This is the first human study of an experimental drug called CKD-512. It aims to find a safe dose and see if the drug, given alone or with an existing immunotherapy (pembrolizumab), can help control advanced solid tumors. The study is for people whose cancer has continued to grow despite all available standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.